Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment

Phase 3obudanersenPositive

AI Analysis

Summary

Ionis Pharmaceuticals has completed enrolment in the pivotal cohort of the Phase III REVEAL study evaluating obudanersen, an RNA-targeted investigational medicine for ankylosing spondylitis.

Clinical Trial Data

Phase

Phase III

Outcome Details

Pivotal cohort enrolment concluded

Importance:5/10

Sentiment:

0.40

Phase 3enrollmentRNA-targeted medicineankylosing spondylitis

Related Companies

$IONS

Read the original article

Published by Clinical Trials Arena on July 7, 2026 9:00 AM

Read Original